Starting in 2024, Swiss patients will face higher costs for original medications compared to generics, encouraging the adoption of cheaper alternatives. Data from health insurer Helsana shows a significant rise in the use of generics among chronically ill individuals, demonstrating the effectiveness of the policy. As of July 2024, the adoption rate of generics increased from 12% to 25%. Health organizations argue that more generics need to be available in the market to maximize savings, while suggesting regulatory changes to lower barriers to entry.